Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).
Nimira Alimohamed(University of Calgary), Steven Yip(University of Calgary), Naveen S. Basappa, Vishal Navani(Hunter Medical Research Institute), Richard M. Lee‐Ying(Alberta Health Services), Pinaki Bose(University of Calgary), Scott North, Michael Kolinsky(University of Alberta), Tracy Jing Xu(University of Calgary), Navdeep Dehar(Occupational Cancer Research Centre), Safiya Karim(University of Saskatchewan), Michelle L. Dean(Alberta Health Services), B. Osborne, Amina Taleb(Alberta Health Services), Joseph D. Ruether, Amanda Williams Gibson(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Megha Murali(Rajiv Gandhi Centre for Biotechnology), Roba Kebebew Banjaw(University of Calgary), Tarek A. Bismar(University of Calgary)
Cited by 0
Related Papers
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
|European Urology|2014|273
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233